LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling

Hypertension

Volumn 50, Issue 6, 2007, Pages 1009-1011

  Paulis, Ludovit ^a,b   Simko, Fedor ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; LA 419; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PLACEBO; UNCLASSIFIED DRUG;

AORTA STENOSIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FIBROSIS; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NOTE; PRIORITY JOURNAL; VASODILATATION;

ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; VENTRICULAR REMODELING;

EID: 36448964430     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.100032     Document Type: Note

References (13)

1. Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol Regul Integr Comp Physiol. 1999;276:R265-R276.
2. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart. 2001;86:368-372.
3. Cheng JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther. 2006;28:666-678.
4. Simko F. Is NO the king? Pathophysiological benefit with uncertain clinical impact. Physiol Res. 2007;56(Suppl 2):in press.
5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133.
6. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol. 2007;151:305-321.
7. Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: beyond vascular nitrate tolerance. Pharmacol Ther. 2005;105:57-68.
8. Lacer. Derivates of isosorbid mononitrate as vasodilator agents with reduced tolerance. WO Patent. 2005;0020420.
9. Vilahur G, Segales E, Casani L, Badimon L. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost. 2004;91:1035-1043.
10. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension. 2007;50:1049-1056.
11. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol. 2001;38(suppl 2):S3-S6.
12. Simko F, Luptak I, Matuskova J, Krajcirovicova K, Sumbalova Z, Kucharska J, Gvozdjakova A, Simko J, Babal P, Pechanova O, Bernatova I. L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension. Eur J Clin Invest. 2005;35:362-368.
13. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res. 2000;49:37-46.